Director, Start-up Strategy and Enrollment Performance, Clinical Operations

BlueRock Therapeutics, a wholly-owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company pioneering a new generation of cellular medicines. Utilizing our proprietary CELL+GENE™ platform, we direct cellular differentiation and genetically engineer cells to create transformative therapies for patients suffering from neurological and ophthalmological diseases. Founded in 2016, BlueRock is at the forefront of the convergence of cell biology and genetic engineering. Our mission is to harness pluripotent stem cell technology and gene editing to deliver authentic, functional cell therapies that address the root causes of disease and offer hope to millions of patients worldwide. What Are We Doing? Our foundational science enables the generation and directed differentiation of universal pluripotent stem cells into authentic, functional cells for allogeneic cellular therapies. We are passionate about realizing the promise of cell and gene therapy, shaping the future of regenerative medicine, and delivering new therapies to patients with limited or no treatment options. About the Role The Director, Start-up Strategy & Enrollment Performance contributes to the strategic and operational leadership across study feasibility, site selection and activation, recruitment strategy, enrollment delivery, and study performance analysis. Serving as a thought partner to the Clinical Operations Study Lead (COSL), this role brings deep content expertise, a strategy- and risk-focused mindset, and strong analytical skills to shape study-specific approaches from start-up through enrollment delivery. The Director develops and then translates strategy into practical study-, country-, and site-level plans, including tactics, metrics, reporting, risk monitoring and oversight methods. This role partners closely with study teams, CROs, vendors, and functional leaders to implement fit-for-purpose strategies, manage specialized vendors, monitor performance, identify risks, and drive timely mitigation and resolution. The Director also builds stakeholder feedback loops, communicates effectively to drive decisions, and creates measurable value through consistent, accountable execution across studies. The Director builds, owns and maintains a scalable, fit-for-purpose operating model for this function. Key Responsibilities: Study Strategy from Start-up through Enrollment Delivery Contribute to the site feasibility, selection and activation strategy; may serve as accountable lead for one or more of these activities depending on study needs and scope Develop, achieve endorsement, and own the study recruitment strategy in alignment with study assumptions e.g., scope, timeline, study population, disease landscape, enrollment strategy, and diversity and retention objectives Serve as a valued thought partner for the COSL (Clinical Operations Study Lead) on the development of the study enrollment strategy and timeline, including performance assumptions and performance monitoring strategy Oversee the collection, analysis and synthesis of available benchmark, historic and ongoing data as it pertains to the relevant strategies Strategy Implementation & Performance Monitoring Translate the recruitment and enrollment strategy into practical study-, country- and site-level plans, tactics, metrics, and performance expectations that support delivery against enrollment targets Lead relevant tactic implementation, including ownership of requirements, insourcing vs. outsourcing strategy, and development oversight; may need to lead the creation of tactics/materials in-house Accountable to develop, oversee, and deliver performance metrics for assigned remit across study start-up to enrollment; monitor progress via KPIs and dashboards, identify risks and make recommendations to the study team Map, analyze and report on the patient funnel from study population to recruitment and prescreening to screening and enrollment; Identify and mitigate bottlenecks Manage or oversee central recruitment referrals to sites to ensure optimal volume and progress through central and site pre-screening Develop a stakeholder feedback loop to optimize the funnel health and site/patient experience, including appropriate degree of selectivity and efficient progression through steps Contribute to and/or own business requirements for metrics, KPIs and dashboards Relationship Management & Operating Model Identify, engage, and manage specialized feasibility, recruitment, and/or enrollment vendors, ensuring performance, quality, timelines, budget awareness, reporting, and service delivery align with study needs and organizational expectations Influence and align internal and external stakeholders to achieve deliverables in an effective, efficient manner Represent study start-up, enrollment and recruitment perspectives in study/program forums and contribute to vendor governance/oversight forums and approaches. Develop and maintain an operating model for the Start-up Strategy & Enrollment Performance function, including relevant SOPs, work instructions, templates, KPIs, and best practices that enable scalable, fit-for-purpose delivery across studies Minimum Requirements Bachelor’s degree in life sciences or related field 10+ years of experience in clinical operations, patient recruitment, and/or clinical trial optimization within the pharmaceutical, biotech and or CRO/vendor setting, with a strong understanding of the clinical trial lifecycle Experience should include exposure to all areas of study/site start-up, recruitment, enrollment, and site performance, with deep expertise and demonstrated success in most if not all these areas Highly skilled strategic thinker who can develop and communicate a comprehensive, agile, operational strategy tailored to the specific needs of the study; not simply a set of tactics Highly adept at identifying and assessing risks, developing practical solutions, and aligning teams with clarity and confidence Strong data-driven mindset, with the ability to translate complex benchmark/historic data, live dashboards, and KPI data into actionable insights Strong business and process-driven mindset with the ability to think beyond individual tasks and issues to create a scalable overarching model Expert vendor management experience in relevant areas of start-up, recruitment, enrollment; skills should include vendor identification, management, performance oversight, timeline and budget creation, and assessment of ROI Excellent knowledge of ICH-GCP, FDA, EMA, applicable regulatory requirements, and quality expectations for clinical trial conduct and patient-facing study activities Excellent stakeholder management, communication, negotiation, influencing, analytical, problem-solving, and prioritization skills across internal functions, senior leaders, CROs, vendors, and partners Experience managing direct reports preferred Ability to thrive in a fast-paced, matrixed, and innovative environment Ability to travel occasionally, up to 15% The estimated compensation range for this position is $ 192,000.00 - $ 204,300.00 per year. Equal Opportunity Workplace: At BlueRock, we welcome and support differences and diversity and we are proud to be an equal opportunity workplace. Please let us know if you require disability-related accommodation or other grounds protected by human rights legislation during the recruitment process so that we can work with you to meet your needs. We may use artificial intelligence (AI) tools to support parts of the hiring process, such as reviewing applications, analyzing resumes, or assessing responses. These tools assist our recruitment team but do not replace human judgment. Final hiring decisions are ultimately made by humans. If you would like more information about how your data is processed, please contact us. BlueRock Therapeutics is a clinical stage cell therapy company focused on creating cellular medicines to treat devastating diseases. We are harnessing the power of cell therapy to create a pipeline of new medicines for people suffering from neurological and ophthalmic diseases. Two of our novel investigational cell therapies, one for the treatment of Parkinson’s disease and one for the treatment of primary photoreceptor diseases, are clinical stage programs. BlueRock was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG that invests in paradigm-shifting breakthrough innovation. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG. Our culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that we are all part of something bigger than ourselves. #J-18808-Ljbffr BlueRock Therapeutics LP